December 19, 2017

Alamo Pharma Services Leadership participates as a speaker and Sponsor of the recent FDA/CMS Summit in Washington, D.C.

Company COO participates in conference panel discussion on “Off Label Developments: The Future of Product Communications”

DOYLESTOWN, Pa. (December 19, 2017) – Peter Marchesini, Chief Operating Officer of Alamo Pharma Services (“Alamo”), participated as one of two panelists in a session at the recent FDA/CMS Summit in Washington, D.C. The summit’s focus was to help attendees better understand the finer points of U.S. regulatory policy as it intersects with breakthrough scientific innovation. The annual conference hosted by KNect365, offers attendees the unique opportunity to learn the latest discoveries in drug programs and also receive formulary guidance directly from decision-makers.

Alamo Pharma Services, Inc. Chief Operating Officer, Peter Marchesini (right), participates in the panel discussion, “Off Label Developments: The Future of Product Communications,” at the recent FDA/CMS Summit in Washington, D.C. Marchesini was joined in the panel by moderator M. Nielsen Hobbs, editor of The Pink Sheet (left), and Kevin Ryan, Senior Director, Compliance and Ethics at Novo Nordisk (center).

During his discussion, “Off Label Developments: The Future of Product Communications,” Marchesini shared his perspective on the current standing on FDA product communications and the implications for 2018. “I was excited to be a part of the FDA/CMS Summit panel and share my insights,” says Marchesini. “In addition to this panel, the summit organizers assembled a tremendous program of workshops, labs, and general sessions highlighted by a truly distinguished group of presenters. Presenting in this conference provided a great opportunity to gain insights from a ‘who’s-who’ of industry leaders on a variety of topics highly relevant to our teams at Alamo and for my own education.”


Featured speakers/presenters at this year’s event included:

  • Janet Woodcock, Director of Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA), who provided a review of 2017 as well as plans for 2018, along with an update from the Office of New Drugs
  • Scott Gottlieb, the 23rd Commissioner of the FDA, who recently launched the “Safety First” and “Safe Use” initiatives designed to improve drug safety management within and outside FDA, respectively


Marchesini’s panel was moderated by M. Nielsen Hobbs, editor of The Pink Sheet, and a journalist with more than 20 years of experience covering the pharmaceutical industry. Also included on the panel was Kevin Ryan, Senior Director, Compliance and Ethics at Novo Nordisk. As a result of the discussion, attendees gained insight in how to better:

  • Ensure their company representatives are utilizing known and understood information about products
  • Understand why the need for fair balance is still appropriate
  • Appreciate the need for compliance training for traditional representatives
  • Value the credibility of the Health Care Provider (HCP)/Patient interaction and why each company has an obligation to make sure the HCP understands the total picture

During his time with Alamo, Marchesini has been able to utilize his more than 25 years of pharmaceutical leadership experience to guide the organization from inception more than six years ago through today. He personally focuses on the business development and operational efforts of the company. Alamo is a key member of the Mission Family of Companies, and Marchesini works closely with the parent company’s leadership to develop and implement plans that will assure both Alamo and Mission’s continued growth. Known for his effective leadership style and strategic thinking, Marchesini was recognized in both 2009 and 2017 as one of the “PharmaVoice 100,” a selection of the 100 most inspiring people in the pharmaceutical industry. He also has a passion and talent for teaching, and is part of the Rutgers University Pharmaceutical MBA program faculty.


The FDA/CMS Summit took place on December 5 and 6, 2017, at Renaissance Washington, D.C., Downtown. For more information on the summit, please visit


About Alamo Pharma Services
Founded in 2011, Alamo Pharma Services offers pharmaceutical and biotech companies vital solutions to bring their products to market efficiently and successfully. Based out of its offices in Doylestown, Pa., Alamo offers companies vast commercialization experience, customized recruiting of sales teams, superior training, and committed support services. For more information regarding Alamo, visit or email


Alamo is part of the Mission Family of Companies, a collection of wholly-owned subsidiaries created by Mission Pharmacal to diversify offerings and build forward-thinking partnerships with other pharmaceutical and biotech companies. Other Mission companies include BioComp Pharma, Inc., a generic drug marketer; ProSolus, Inc., a transdermal drug developer and manufacturer; Espada Dermatology, Inc., a prescription and esthetic dermatology company; as well as BexR Logistix, LLC and their subsidiary company, EPIC Fulfillment, Inc., the logistics and fulfillment arms of Mission. To learn more, please visit

# # #

Are you a media professional? We’re happy to help you build your story with information about Alamo Pharma Services or interviews with company representatives.